Cytek Biosciences Inc (CTKB) — Cash Flow Reinvestment Rate
Cytek Biosciences Inc (CTKB) has a Cash Flow Reinvestment Rate of 166.57x as of June 2025, reinvesting $17.99 Million (capex $1.58 Million plus investments $-16.41 Million) from operating cash flow of $108.00K. Explore reinvestment intensity of Cytek Biosciences Inc to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cytek Biosciences Inc Cash Flow Reinvestment Rate (2020–2024)
Historical reinvestment intensity for Cytek Biosciences Inc across 4 annual periods. Also explore Cytek Biosciences Inc asset portfolio for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for Cytek Biosciences Inc (2020–2024)
Year-by-year capital reinvestment analysis for Cytek Biosciences Inc. For live market cap and broader valuation context, see CTKB market cap overview.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 3.41x | $86.50 Million | $25.38 Million | $3.52 Million | ▼ -89.9% |
| 2023 | 33.87x | $178.85 Million | $5.28 Million | $4.83 Million | ▲ +518.4% |
| 2021 | 5.48x | $25.36 Million | $4.63 Million | $4.36 Million | ▲ +2582.8% |
| 2020 | 0.20x | $3.09 Million | $15.16 Million | $1.55 Million | — |